Cervical Cancer

Restricted access
Overview An estimated 12,200 new cases of cervical cancer will be diagnosed in the United States in 2010, and 4200 people will die of the disease.1 Cervical cancer rates are decreasing among women in the United States, although incidence remains high among Hispanic/Latino, black, and Asian women.2–5 However, cervical cancer is a major world health problem for women. The global yearly incidence of cervical cancer for 2002 was 493,200; the annual death rate was 273,500. It is the third most common cancer in women worldwide,6,7 with 78% of cases occurring in developing countries, where cervical cancer is the second most frequent cause of cancer death in women. Persistent human papillomavirus (HPV) infection is regarded as the most important factor contributing to the development of cervical cancer. A relationship seems to exist between the incidence of cervical cancer and the prevalence of HPV in the population. The prevalence of chronic HPV in countries with a high incidence of cervical cancer is 10% to 20%, whereas its prevalence in low-incidence countries is 5% to 10%.6 Immunization against HPV prevents infection with certain types of HPV and, thus, is expected to prevent specific HPV cancer in women (see NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Cervical Cancer Screening, in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org).8–12 Other epidemiologic risk factors associated with cervical cancer are a history of smoking, parity, contraceptive use, early age at onset of coitus, larger number...
  • 1.

    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277300.

  • 2.

    Barnholtz-Sloan J, Patel N, Rollison D. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 2009;20:11291138.

    • Search Google Scholar
    • Export Citation
  • 3.

    Wang SS, Carreon JD, Gomez SL, Devesa SS. Cervical cancer incidence among 6 asian ethnic groups in the United States, 1996 through 2004. Cancer 2010;116:949956.

    • Search Google Scholar
    • Export Citation
  • 4.

    Howe HL, Wu X, Ries LAG. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:17111742.

    • Search Google Scholar
    • Export Citation
  • 5.

    Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005;103:12581264.

    • Search Google Scholar
    • Export Citation
  • 6.

    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74108.

  • 7.

    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:21372150.

    • Search Google Scholar
    • Export Citation
  • 8.

    Villa LL, Costa RL, Petta CA. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271278.

    • Search Google Scholar
    • Export Citation
  • 9.

    Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:18611868.

    • Search Google Scholar
    • Export Citation
  • 10.

    Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:19151927.

  • 11.

    Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007;38:189197.

    • Search Google Scholar
    • Export Citation
  • 12.

    Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007;177:469479.

    • Search Google Scholar
    • Export Citation
  • 13.

    Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007;120:885891.

    • Search Google Scholar
    • Export Citation
  • 14.

    Bray F, Loos AH, McCarron P. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677686.

    • Search Google Scholar
    • Export Citation
  • 15.

    Watson M, Saraiya M, Benard V. Burden of cervical cancer in the United States, 1998-2003. Cancer 2008;113:28552864.

  • 16.

    Bray F, Carstensen B, Moller H. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:21912199.

    • Search Google Scholar
    • Export Citation
  • 17.

    Wang SS, Sherman ME, Hildesheim A. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer 2004;100:10351044.

    • Search Google Scholar
    • Export Citation
  • 18.

    Castellsague X, Diaz M, de Sanjose S. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303315.

    • Search Google Scholar
    • Export Citation
  • 19.

    Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009;125:525529.

  • 20.

    Dahlstrom LA, Ylitalo N, Sundstrom K. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010;127:19231930.

    • Search Google Scholar
    • Export Citation
  • 21.

    ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas. Number 35, May 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;78:7991.

    • Search Google Scholar
    • Export Citation
  • 22.

    Gold MA, Tian C, Whitney CW. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Cancer 2008;112:19541963.

    • Search Google Scholar
    • Export Citation
  • 23.

    Monk BJ, Tian C, Rose PG, Lanciano R. Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials. Gynecol Oncol 2007;105:427433.

    • Search Google Scholar
    • Export Citation
  • 24.

    Ramirez PT, Slomovitz BM, Soliman PT. Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol 2006;102:252255.

    • Search Google Scholar
    • Export Citation
  • 25.

    Abu-Rustum NR, Gemignani ML, Moore K. Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy. Gynecol Oncol 2003;91:402409.

    • Search Google Scholar
    • Export Citation
  • 26.

    Chi DS. Laparoscopy in gynecologic malignancies. Oncology (Williston Park) 1999;13:773782.

  • 27.

    Chen Y, Xu H, Li Y. The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients. Ann Surg Oncol 2008;15:28472855.

    • Search Google Scholar
    • Export Citation
  • 28.

    Puntambekar SP, Palep RJ, Puntambekar SS. Laparoscopic total radical hysterectomy by the Pune technique: our experience of 248 cases. J Minim Invasive Gynecol 2007;14:682689.

    • Search Google Scholar
    • Export Citation
  • 29.

    Lowe MP, Chamberlain DH, Kamelle SA. A multi-institutional experience with robotic-assisted radical hysterectomy for early stage cervical cancer. Gynecol Oncol 2009;113:191194.

    • Search Google Scholar
    • Export Citation
  • 30.

    Nezhat FR, Datta MS, Liu C. Robotic radical hysterectomy versus total laparoscopic radical hysterectomy with pelvic lymphadenectomy for treatment of early cervical cancer. JSLS 2008;12:227237.

    • Search Google Scholar
    • Export Citation
  • 31.

    Cantrell LA, Mendivil A, Gehrig PA, Boggess JF. Survival outcomes for women undergoing type III robotic radical hysterectomy for cervical cancer: a 3-year experience. Gynecol Oncol 2010;117:260265.

    • Search Google Scholar
    • Export Citation
  • 32.

    Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009;105:107108.

  • 33.

    Moore DH. Surgical staging and cervical cancer: after 30 years, have we reached a conclusion? Cancer 2008;112:18741876.

  • 34.

    Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103104.

  • 35.

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.

  • 36.

    Park JY, Kim EN, Kim DY. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol 2008;108:486492.

    • Search Google Scholar
    • Export Citation
  • 37.

    Boughanim M, Leboulleux S, Rey A. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol 2008;26:25582561.

    • Search Google Scholar
    • Export Citation
  • 38.

    Baalbergen A, Veenstra Y, Stalpers LL, Ansink AC. Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev 2010:CD006248.

    • Search Google Scholar
    • Export Citation
  • 39.

    Park JY, Kim DY, Kim JH. Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix. Br J Cancer 2010;102:16921698.

    • Search Google Scholar
    • Export Citation
  • 40.

    Landoni F, Maneo A, Colombo A. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535540.

    • Search Google Scholar
    • Export Citation
  • 41.

    Keys HM, Bundy BN, Stehman FB. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:11541161.

    • Search Google Scholar
    • Export Citation
  • 42.

    Morris M, Eifel PJ, Lu J. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:11371143.

    • Search Google Scholar
    • Export Citation
  • 43.

    Peters WA, Liu PY, Barrett RJ. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:16061613.

    • Search Google Scholar
    • Export Citation
  • 44.

    Whitney CW, Sause W, Bundy BN. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:13391348.

    • Search Google Scholar
    • Export Citation
  • 45.

    Rose PG, Bundy BN, Watkins EB. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:11441153.

    • Search Google Scholar
    • Export Citation
  • 46.

    Thomas GM. Improved treatment for cervical cancer—concurrent chemotherapy and radiotherapy. N Engl J Med 1999;340:11981200.

  • 47.

    Rose PG, Ali S, Watkins E. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:28042810.

    • Search Google Scholar
    • Export Citation
  • 48.

    Eifel PJ, Winter K, Morris M. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872880.

    • Search Google Scholar
    • Export Citation
  • 49.

    Stehman FB, Ali S, Keys HM. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol 2007;197:16.

    • Search Google Scholar
    • Export Citation
  • 50.

    Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:58025812.

    • Search Google Scholar
    • Export Citation
  • 51.

    Pearcey R, Miao Q, Kong W. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study. J Clin Oncol 2007;25:23832388.

    • Search Google Scholar
    • Export Citation
  • 52.

    King M, McConkey C, Latief TN. Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol (R Coll Radiol) 2006;18:3845.

    • Search Google Scholar
    • Export Citation
  • 53.

    Tan LT, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer--the Addenbrooke's experience. Clin Oncol (R Coll Radiol) 2008;20:358364.

    • Search Google Scholar
    • Export Citation
  • 54.

    Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007;25:29522965.

    • Search Google Scholar
    • Export Citation
  • 55.

    Cetina L, Garcia-Arias A, Uribe Mde J. Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer. Eur J Gynaecol Oncol 2008;29:608612.

    • Search Google Scholar
    • Export Citation
  • 56.

    Dubay RA, Rose PG, O'Malley DM. Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol 2004;94:121124.

    • Search Google Scholar
    • Export Citation
  • 57.

    Higgins RV, Naumann WR, Hall JB, Haake M. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol 2003;89:499503.

    • Search Google Scholar
    • Export Citation
  • 58.

    Lorvidhaya V, Chitapanarux I, Sangruchi S. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003;55:12261232.

    • Search Google Scholar
    • Export Citation
  • 59.

    Wong LC, Ngan HY, Cheung AN. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol 1999;17:20552060.

  • 60.

    Poveda A, Gonzalez-Martin A. Multimodality treatment in locoregional gynecological cancer: cervical cancer treatment update. Ann Oncol 2008;19(Suppl 7):7076.

    • Search Google Scholar
    • Export Citation
  • 61.

    Duenas-Gonzalez A, Zarba JJ, Alcedo JC. A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract CRA5507.

    • Search Google Scholar
    • Export Citation
  • 62.

    Koliopoulos G, Sotiriadis A, Kyrgiou M. Conservative surgical methods for FIGO stage IA2 squamous cervical carcinoma and their role in preserving women's fertility. Gynecol Oncol 2004;93:469473.

    • Search Google Scholar
    • Export Citation
  • 63.

    Wright JD, NathavithArana R, Lewin SN. Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol 2010;115:585590.

    • Search Google Scholar
    • Export Citation
  • 64.

    Bernardini M, Barrett J, Seaward G, Covens A. Pregnancy outcomes in patients after radical trachelectomy. Am J Obstet Gynecol 2003;189:13781382.

    • Search Google Scholar
    • Export Citation
  • 65.

    Boss EA, van Golde RJ, Beerendonk CC, Massuger LF. Pregnancy after radical trachelectomy: a real option? Gynecol Oncol 2005;99:152156.

  • 66.

    Plante M, Renaud MC, Hoskins IA, Roy M. Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 2005;98:310.

    • Search Google Scholar
    • Export Citation
  • 67.

    Marchiole P, Benchaib M, Buenerd A. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH). Gynecol Oncol 2007;106:132141.

    • Search Google Scholar
    • Export Citation
  • 68.

    Diaz JP, Sonoda Y, Leitao MM. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol 2008;111:255260.

    • Search Google Scholar
    • Export Citation
  • 69.

    Shepherd JH, Spencer C, Herod J, Ind TE. Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer-cumulative pregnancy rate in a series of 123 women. BJOG 2006;113:719724.

    • Search Google Scholar
    • Export Citation
  • 70.

    Landoni F, Zanagnolo V, Lovato-Diaz L. Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study). Int J Gynecol Cancer 2007;17:623628.

    • Search Google Scholar
    • Export Citation
  • 71.

    Shimada M, Kigawa J, Nishimura R. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol 2006;101:234237.

  • 72.

    Lecuru F, Bats A, Mathevet P. Impact of sentinel lymph node biopsy on staging of early cervical cancer: Results of a prospective, multicenter study [abstract]. J Clin Oncol 2009;27(Suppl 18):Abstract CRA5506.

    • Search Google Scholar
    • Export Citation
  • 73.

    Altgassen C, Hertel H, Brandstadt A. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol 2008;26:29432951.

    • Search Google Scholar
    • Export Citation
  • 74.

    Fader AN, Edwards RP, Cost M. Sentinel lymph node biopsy in early-stage cervical cancer: utility of intraoperative versus postoperative assessment. Gynecol Oncol 2008;111:1317.

    • Search Google Scholar
    • Export Citation
  • 75.

    Selman TJ, Mann C, Zamora J. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. CMAJ 2008;178:855862.

    • Search Google Scholar
    • Export Citation
  • 76.

    van de Lande J, Torrenga B, Raijmakers PG. Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. Gynecol Oncol 2007;106:604613.

    • Search Google Scholar
    • Export Citation
  • 77.

    Schneider A. The sentinel concept in patients with cervical cancer. J Surg Oncol 2007;96:337341.

  • 78.

    Pandit-Taskar N, Gemignani ML, Lyall A. Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. Gynecol Oncol 2010;117:5964.

    • Search Google Scholar
    • Export Citation
  • 79.

    Goff BA, Muntz HG, Paley PJ. Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol 1999;74:436442.

  • 80.

    Monk BJ, Wang J, Im S. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol 2005;96:721728.

    • Search Google Scholar
    • Export Citation
  • 81.

    Chernofsky MR, Felix JC, Muderspach LI. Influence of quantity of lymph vascular space invasion on time to recurrence in women with early-stage squamous cancer of the cervix. Gynecol Oncol 2006;100:288293.

    • Search Google Scholar
    • Export Citation
  • 82.

    Marchiole P, Buenerd A, Benchaib M. Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective case-control surgico-pathological study. Gynecol Oncol 2005;97:727732.

    • Search Google Scholar
    • Export Citation
  • 83.

    Sedlis A, Bundy BN, Rotman MZ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol 1999;73:177183.

    • Search Google Scholar
    • Export Citation
  • 84.

    Rotman M, Sedlis A, Piedmonte MR. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006;65:169176.

    • Search Google Scholar
    • Export Citation
  • 85.

    Bodurka-Bevers D, Morris M, Eifel PJ. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000;78:187193.

    • Search Google Scholar
    • Export Citation
  • 86.

    Morice P, Deyrolle C, Rey A. Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 2004;15:218223.

    • Search Google Scholar
    • Export Citation
  • 87.

    Elit L, Fyles AW, Devries MC. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009;114:528535.

  • 88.

    Brooks RA, Rader JS, Dehdashti F. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009;112:104109.

    • Search Google Scholar
    • Export Citation
  • 89.

    Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007;298:22892295.

    • Search Google Scholar
    • Export Citation
  • 90.

    Sironi S, Picchio M, Landoni C. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging 2007;34:472479.

    • Search Google Scholar
    • Export Citation
  • 91.

    Zanagnolo V, Ming L, Gadducci A. Surveillance procedures for patients with cervical carcinoma: a review of the literature. Int J Gynecol Cancer 2009;19:194201.

    • Search Google Scholar
    • Export Citation
  • 92.

    Chung HH, Jo H, Kang WJ. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529534.

    • Search Google Scholar
    • Export Citation
  • 93.

    Chaturvedi AK, Kleinerman RA, Hildesheim A. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol 2009;27:967973.

    • Search Google Scholar
    • Export Citation
  • 94.

    Chaturvedi AK, Engels EA, Gilbert ES. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:16341643.

    • Search Google Scholar
    • Export Citation
  • 95.

    Kumar S, Shah JP, Bryant CS. Radiation-associated endometrial cancer. Obstet Gynecol 2009;113:319325.

  • 96.

    Thomas GM, Dembo AJ, Myhr T. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer 1993;3:193198.

    • Search Google Scholar
    • Export Citation
  • 97.

    Kim JS, Kim SY, Kim KH, Cho MJ. Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2003;55:12471253.

    • Search Google Scholar
    • Export Citation
  • 98.

    Chung YL, Jian JJ, Cheng SH. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study. Gynecol Oncol 2005;97:126135.

    • Search Google Scholar
    • Export Citation
  • 99.

    Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 2005;99:153159.

    • Search Google Scholar
    • Export Citation
  • 100.

    Goldberg GL, Sukumvanich P, Einstein MH. Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol 2006;101:261268.

    • Search Google Scholar
    • Export Citation
  • 101.

    Morley GW, Hopkins MP, Lindenauer SM, Roberts JA. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 1989;74:934943.

    • Search Google Scholar
    • Export Citation
  • 102.

    Fleisch MC, Pantke P, Beckmann MW. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol 2007;95:476484.

    • Search Google Scholar
    • Export Citation
  • 103.

    Tran PT, Su Z, Hara W. Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys 2007;69:504511.

    • Search Google Scholar
    • Export Citation
  • 104.

    Rutledge FN, Smith JP, Wharton JT, O'Quinn AG. Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol 1977;129:881892.

  • 105.

    Symmonds RE, Pratt JH, Webb MJ. Exenterative operations: experience with 198 patients. Am J Obstet Gynecol 1975;121:907918.

  • 106.

    Soper JT, Secord AA, Havrilesky LJ. Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity. Int J Gynecol Cancer 2007;17:298303.

    • Search Google Scholar
    • Export Citation
  • 107.

    Mirhashemi R, Averette HE, Lambrou N. Vaginal reconstruction at the time of pelvic exenteration: a surgical and psychosexual analysis of techniques. Gynecol Oncol 2002;87:3945.

    • Search Google Scholar
    • Export Citation
  • 108.

    Turns D. Psychosocial issues: pelvic exenterative surgery. J Surg Oncol 2001;76:224236.

  • 109.

    Spanos WJ Jr, Perez CA, Marcus S. Effect of rest interval on tumor and normal tissue response--a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502). Int J Radiat Oncol Biol Phys 1993;25:399403.

    • Search Google Scholar
    • Export Citation
  • 110.

    Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer 2007;109:14621470.

  • 111.

    Moore DH, Blessing JA, McQuellon RP. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:31133119.

    • Search Google Scholar
    • Export Citation
  • 112.

    Long HJ III, Bundy BN, Grendys EC Jr. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005;23:46264633.

    • Search Google Scholar
    • Export Citation
  • 113.

    Thigpen T, Shingleton H, Homesley H. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981;48:899903.

    • Search Google Scholar
    • Export Citation
  • 114.

    Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 2008;6:5357.

  • 115.

    Tao X, Hu W, Ramirez PT, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 2008;110:6771.

  • 116.

    Monk BJ, Sill MW, McMeekin DS. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:46494655.

    • Search Google Scholar
    • Export Citation
  • 117.

    Moore KN, Herzog TJ, Lewin S. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007;105:299303.

    • Search Google Scholar
    • Export Citation
  • 118.

    Tinker AV, Bhagat K, Swenerton KD, Hoskins PJ. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol 2005;98:5458.

    • Search Google Scholar
    • Export Citation
  • 119.

    Pectasides D, Fountzilas G, Papaxoinis G. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. Int J Gynecol Cancer 2009;19:777781.

    • Search Google Scholar
    • Export Citation
  • 120.

    Saito I, Kitagawa R, Fukuda H. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol 2010;40:9093.

    • Search Google Scholar
    • Export Citation
  • 121.

    Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol 2009;36:170180.

    • Search Google Scholar
    • Export Citation
  • 122.

    Thigpen JT, Blessing JA, DiSaia PJ. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;32:198202.

    • Search Google Scholar
    • Export Citation
  • 123.

    Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008;34:603613.

  • 124.

    McGuire WP, Arseneau J, Blessing JA. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:14621468.

    • Search Google Scholar
    • Export Citation
  • 125.

    Weiss GR, Green S, Hannigan EV. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 1990;39:332336.

    • Search Google Scholar
    • Export Citation
  • 126.

    Kudelka AP, Winn R, Edwards CL. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997;8:657661.

    • Search Google Scholar
    • Export Citation
  • 127.

    McGuire WP, Blessing JA, Moore D. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996;14:792795.

    • Search Google Scholar
    • Export Citation
  • 128.

    Monk BJ, Sill MW, Burger RA. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009;27:10691074.

    • Search Google Scholar
    • Export Citation
  • 129.

    Garcia AA, Blessing JA, Vaccarello L, Roman LD. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 2007;30:428431.

    • Search Google Scholar
    • Export Citation
  • 130.

    Look KY, Blessing JA, Gallup DG, Lentz SS. A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1996;19:439441.

    • Search Google Scholar
    • Export Citation
  • 131.

    Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2005;96:103107.

    • Search Google Scholar
    • Export Citation
  • 132.

    Coleman RE, Harper PG, Gallagher C. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1986;18:280283.

    • Search Google Scholar
    • Export Citation
  • 133.

    Sutton GP, Blessing JA, McGuire WP. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993;168:805807.

    • Search Google Scholar
    • Export Citation
  • 134.

    Verschraegen CF, Levy T, Kudelka AP. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15:625631.

    • Search Google Scholar
    • Export Citation
  • 135.

    Wagenaar HC, Pecorelli S, Mangioni C. Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. Eur J Cancer 2001;37:16241628.

    • Search Google Scholar
    • Export Citation
  • 136.

    Bookman MA, Blessing JA, Hanjani P. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000;77:446449.

    • Search Google Scholar
    • Export Citation
  • 137.

    Muderspach LI, Blessing JA, Levenback C, Moore JL. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001;81:213215.

    • Search Google Scholar
    • Export Citation
  • 138.

    Miller DS, Blessing JA, Bodurka DC. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008;110:6570.

    • Search Google Scholar
    • Export Citation
  • 139.

    Muggia FM, Blessing JA, Method M. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:639643.

    • Search Google Scholar
    • Export Citation
  • 140.

    Castells MC, Tennant NM, Sloane DE. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574580.

    • Search Google Scholar
    • Export Citation
  • 141.

    Sampson HA, Munoz-Furlong A, Campbell RL. Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:373380.

    • Search Google Scholar
    • Export Citation
  • 142.

    Manivannan V, Decker WW, Stead LG. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med 2009;2:35.

    • Search Google Scholar
    • Export Citation
  • 143.

    Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601609.

  • 144.

    Markman M, Zanotti K, Peterson G. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:46114614.

    • Search Google Scholar
    • Export Citation
  • 145.

    Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99:393399.

    • Search Google Scholar
    • Export Citation
  • 146.

    Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004;95:370376.

    • Search Google Scholar
    • Export Citation
  • 147.

    Monie A, Tsen SW, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Expert Rev Vaccines 2009;8:12211235.

  • 148.

    Hung C-F, Ma B, Monie A. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008;8:421439.

    • Search Google Scholar
    • Export Citation
  • 149.

    Huang CF, Monie A, Weng WH, Wu T. DNA vaccines for cervical cancer. Am J Transl Res 2010;2:7587.

  • 150.

    Gonzalez-Cortijo L, Carballo N, Gonzalez-Martin A. Novel chemotherapy approaches in chemoradiation protocols. Gynecol Oncol 2008;110:S4548.

  • 151.

    Gonzalez Martin A. Molecular biology of cervical cancer. Clin Transl Oncol 2007;9:347354.

  • 152.

    Erickson-Whitmann B, Rownd J, Khater K. Biologic and physical aspects of radiation oncology. In: Barakat R, Markman M, Randall M, eds. Principles and Practice of Gynecology Oncology, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:325380.

    • Search Google Scholar
    • Export Citation
  • 153.

    Beriwal S, Gan GN, Heron DE. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2007;68:166171.

    • Search Google Scholar
    • Export Citation
  • 154.

    Chen MF, Tseng CJ, Tseng CC. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:14381444.

    • Search Google Scholar
    • Export Citation
  • 155.

    Chen MF, Tseng CJ, Tseng CC. Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients. Cancer J 2008;14:200206.

    • Search Google Scholar
    • Export Citation
  • 156.

    Salama JK, Mundt AJ, Roeske J, Mehta N. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys 2006;65:11701176.

    • Search Google Scholar
    • Export Citation
  • 157.

    Small W, Mell LK, Anderson P. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2008;71:428434.

    • Search Google Scholar
    • Export Citation
  • 158.

    Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992;25:273279.

  • 159.

    Girinsky T, Rey A, Roche B. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27:10511056.

    • Search Google Scholar
    • Export Citation
  • 160.

    Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 1993;25:391397.

    • Search Google Scholar
    • Export Citation
  • 161.

    Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:12751288.

    • Search Google Scholar
    • Export Citation
  • 162.

    Petereit DG, Sarkaria JN, Chappell R. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:13011307.

    • Search Google Scholar
    • Export Citation
  • 163.

    Swenson RE, Goff BA, Koh WJ. Cancer in the pregnant patient. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:12791311.

    • Search Google Scholar
    • Export Citation
  • 164.

    van de Nieuwenhof HP, van Ham MA, Lotgering FK, Massuger LF. First case of vaginal radical trachelectomy in a pregnant patient. Int J Gynecol Cancer 2008;18:13811385.

    • Search Google Scholar
    • Export Citation
  • 165.

    Ben-Arie A, Levy R, Lavie O. Conservative treatment of stage IA2 squamous cell carcinoma of the cervix during pregnancy. Obstet Gynecol 2004;104:11291131.

    • Search Google Scholar
    • Export Citation
  • 166.

    Abu-Rustum NR, Tal MN, DeLair D. Radical abdominal trachelectomy for stage IB1 cervical cancer at 15-week gestation. Gynecol Oncol 2010;116:151152.

    • Search Google Scholar
    • Export Citation
  • 167.

    Gurney EP, Blank SV. Postpartum radical trachelectomy for IB1 squamous cell carcinoma of the cervix diagnosed in pregnancy. Am J Obstet Gynecol 2009;201:e810.

    • Search Google Scholar
    • Export Citation
  • 168.

    Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007;25:29752982.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 494 371 194
PDF Downloads 60 33 5
EPUB Downloads 0 0 0